摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

甲基(1S,6R)-6-甲基-3-环己烯-1-羧酸酯 | 15111-54-3

中文名称
甲基(1S,6R)-6-甲基-3-环己烯-1-羧酸酯
中文别名
——
英文名称
(+/-)-cis-1-carbomethoxy-2-methyl-4-cyclohexene
英文别名
methyl cis-6-methyl-3-cyclohexene-1-carboxylate;cis-2-Methylcyclohex-4-en-1-carbonsaeuremethylester;methyl (1S,6R)-6-methylcyclohex-3-ene-1-carboxylate
甲基(1S,6R)-6-甲基-3-环己烯-1-羧酸酯化学式
CAS
15111-54-3;62266-63-1;88204-99-3;117065-51-7;117065-52-8;126060-19-3;134877-09-1
化学式
C9H14O2
mdl
——
分子量
154.209
InChiKey
SVMRMDDGGIZFQN-SFYZADRCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    188.7±19.0 °C(Predicted)
  • 密度:
    0.980±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:f6ed33b7a6636e509581b3dc936114b7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    甲基(1S,6R)-6-甲基-3-环己烯-1-羧酸酯 在 palladium on activated charcoal 氢气 作用下, 以100%的产率得到(-)-cis-1-carbomethoxy-2-methylcyclohexane
    参考文献:
    名称:
    Enzymes in organic synthesis 49. Resolutions of racemic monocyclic esters with pig liver esterase.
    摘要:
    Pig liver esterase (PLE)- catalyzed hydrolyses of the racemic methyl esters of cyclobutane-, cyclohexane-, and cyclohex-4-ene-carboxylic acids bearing cis-2-methyl or cis-2-bromomethyl substituents are highly stereoselective, giving the corresponding acid products of greater-than-or-equal-to 97% ee. The stereoselectivity of the enzyme exhibits the expected reversal for such compounds, with the absolute configurations of the cyclobutane and cyclohexane acids being of the opposite absolute configuration types, and cyclopentane substrates such as cis-1-carbomethoxy-2-methylcyclopentane representing the change-over structures and giving products of only 22% ee. This stereoselectivity reversal, and the absolute configurations preferred, are as predicted by the recently proposed active site model for the enzyme.
    DOI:
    10.1016/s0957-4166(00)82360-5
  • 作为产物:
    参考文献:
    名称:
    Enzymes in organic synthesis 49. Resolutions of racemic monocyclic esters with pig liver esterase.
    摘要:
    Pig liver esterase (PLE)- catalyzed hydrolyses of the racemic methyl esters of cyclobutane-, cyclohexane-, and cyclohex-4-ene-carboxylic acids bearing cis-2-methyl or cis-2-bromomethyl substituents are highly stereoselective, giving the corresponding acid products of greater-than-or-equal-to 97% ee. The stereoselectivity of the enzyme exhibits the expected reversal for such compounds, with the absolute configurations of the cyclobutane and cyclohexane acids being of the opposite absolute configuration types, and cyclopentane substrates such as cis-1-carbomethoxy-2-methylcyclopentane representing the change-over structures and giving products of only 22% ee. This stereoselectivity reversal, and the absolute configurations preferred, are as predicted by the recently proposed active site model for the enzyme.
    DOI:
    10.1016/s0957-4166(00)82360-5
点击查看最新优质反应信息

文献信息

  • Cyclohexene derivative and method of producing the same
    申请人:Japan Tobacco Inc.
    公开号:US05329042A1
    公开(公告)日:1994-07-12
    Provided is a novel (1R, 2S)-1-acyl-2-carboxycyclohex-4-ene derivative represented by the following general formula [I], and its producing method, ##STR1## (where R.sup.1 represents a hydrogen atom, a lower alkyl group, or substituted or unsubstituted aryl group, and R.sup.2 represents a hydrogen atom, or a lower alkyl group). Also provided is a method of producing a (3S, 4R)-4-substituted-3-carboxycyclopentanone derivative represented by the following general formula [A], ##STR2## (where R.sup.1 and R.sup.2 are the same as those mentioned above).
    提供了一种由下列通用式[I]表示的新型(1R,2S)-1-酰基-2-羧基环己-4-烯衍生物及其制备方法:##STR1##(其中,R1代表氢原子、低碳基、取代或未取代的芳基;R2代表氢原子或低碳基)。还提供了一种制备下列通用式[A]所表示的(3S,4R)-4-取代-3-羧基环戊酮衍生物的方法:##STR2##(其中,R1和R2与上述相同)。
  • QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    申请人:KOGA Yuji
    公开号:US20120136025A1
    公开(公告)日:2012-05-31
    Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R 0 )C(O)-lower alkylene-CO 2 R 0 , lower alkylene-CO 2 R 0 , lower alkenylene-CO 2 R 0 , —O-lower alkylene-CO 2 R 0 , —O-(lower alkylene which may be substituted with —CO 2 R 0 )-aryl or —O-lower alkenylene-CO 2 R 0 (wherein R 0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. The quinolone derivatives have excellent platelet aggregation inhibitory activity. A method of using the compounds is also disclosed.
    本发明涉及喹诺酮衍生物,其特征在于它们在1-位具有较低烷基、环烷基或类似物;在3-位具有-N(R0)C(O)-较低烷基烯基-CO2R0、较低烷基-CO2R0、较低烯基-CO2R0、-O-较低烷基-CO2R0、-O-(可能被取代为-CO2R0的较低烷基)芳基或-O-较低烯基-CO2R0(其中R0为H或较低烷基);在6-位具有卤素;在7-位具有被环状取代基取代的氨基,或其药学上可接受的盐,具有出色的P2Y12抑制活性。这些喹诺酮衍生物具有优异的血小板聚集抑制活性。本发明还公开了一种使用这些化合物的方法。
  • Bridged Macrocyclic Module Compositions
    申请人:Whiteford Jeffery A.
    公开号:US20130081999A1
    公开(公告)日:2013-04-04
    This invention is related to the fields of organic chemistry and nanotechnology. In particular, it relates to materials and methods for the preparation of organic synthons and bridged macrocyclic module components. The bridge macrocyclic module compounds may be used to prepare macrocyclic module compositions such as nanofilms, which may be useful for filtration.
    该发明涉及有机化学和纳米技术领域。具体而言,它涉及有机合成物和桥连的大环模块组分的制备材料和方法。桥连的大环模块化合物可用于制备大环模块组合物,如纳米薄膜,这些组合物可能对过滤有用。
  • 13C and 1H chemical shift assignments and conformation confirmation of trimedlure-Y via 2-D NMR
    作者:J.D. Warthen、R.M. Waters、T.P. McGovern
    DOI:10.1016/0584-8539(87)80240-4
    日期:1987.1
  • Christol,H. et al., Bulletin de la Societe Chimique de France, 1969, p. 962 - 967
    作者:Christol,H. et al.
    DOI:——
    日期:——
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物